Aripiprazole for the treatment of irritability associated with autism

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 4, 2011, Pages 635-640

  Farmer, Cristan Ann ^a   Aman, Michael G ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Antipsychotic; Aripiprazole; Autism; Efficacy; Irritability

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; FLUOXETINE; FLUVOXAMINE; NEUROLEPTIC AGENT; OXCARBAZEPINE; PLACEBO; RISPERIDONE; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; VALPROIC ACID;

AKATHISIA; ARTICLE; AUTISM; BIPOLAR I DISORDER; BODY WEIGHT; DOUBLE BLIND PROCEDURE; DOUBLE BLIND PROCEDURE (TOPIC); DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EXTRAPYRAMIDAL SYMPTOM; GENETIC VARIABILITY; HUMAN; HYPERGLYCEMIA; HYPERSALIVATION; IRRITABILITY; MOOD DISORDER; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; VOMITING; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; HUMANS; IRRITABLE MOOD; PIPERAZINES; QUINOLONES; RISPERIDONE;

EID: 79951641424     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.557661     Document Type: Article

References (28)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. American Psychiatric Association, Washington, DC; 2000
2. Autism and developmental disabilities monitoring network surveillance year 2002. Principal investigators and centers for disease control and prevention. Prevalence of autism spectrum disorders - autism and developmental disabilities monitoring network, 14 sites, United States, 2002. MMQR Surveill Summ 2007;56:12-28
3. Chakrabarti S, Fombonne E. Pervasive developmental disorders in preschool children: conformation of high prevalence. Am J Psychiatry 2005;162:1133-41 (Pubitemid 40770696)
4. Fombonne E, Zakarian R, Bennett A, et al. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics 2006;118:e139-50
5. Lecavalier L. Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification. J Autism Dev Disord 2006;36:1101-14 (Pubitemid 46020362)
6. Kanne M, Mazurek M. Aggression in children and adolescents with ASD: prevalence and risk factors. J Autism Dev Disord 2010: published online 20 October 2010, doi: 10.1007/s10803-010-1118-4
7. Farmer C, Aman M. Aggressive behavior in a sample of children with autism spectrum disorders. Res Autism Spec Dis 2010;5:317-23
8. Aman M, Lam K, Van Bourgondien M. Medication patterns in patients with autism: temporal, regional, and demographic influences. J Child Adolesc Psychopharmacol 2005;15:116-26 (Pubitemid 40365921)
9. Janssen(Titusville, NJ). Risperidone [package insert]. July revision, 2009
10. Otsuka Pharmaceutical Co., Ltd (Tokyo, Japan). Aripiprazole [package insert]. November revision, 2009
11. Greenaway M, Elbe D. Focus on aripiprazole: a review of its use in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry 2009;18:250-260
12. Erickson C, Stigler K, Posey D, McDougle C. Aripiprazole in autism spectrum disorders and fragile X syndrome. Neurotherapeutics 2010;7:258-63
13. DeLeon A, Patel N, Crimson M. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 2004;26:649-66 (Pubitemid 38736956)
14. Valicenti-McDermott M, Demb H. Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. J Child Adolesc Psychopharmacol 2006;16:549-60 (Pubitemid 44737210)
15. Masi G, Cosenza A, Millepiedi S, et al. Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective study. CNS Drugs 2009;23:511-21
16. Stigler K, Posey D, McDougle C. Case report: aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol 2004;14:455-63 (Pubitemid 39473132)
17. Stigler K, Diener J, Kohn A, et al. Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study. J Child Adolesc Psychopharmacol 2009;19:265-74
18. Aman M, Singh N. Aberrant behavior checklist manual. Slosson Educational Publications, East Aurora, NY; 1986
19. Sparrow S, Cicchetti D, Balla D. Vineland Adaptive Behavior Scales. 2nd edition. Survey Interview Form/ Caregiver Rating Form, Pearson Assessments, Linovia, MN; 2005
20. Scahill L, Riddle M, McSwiggin-Hardin M, et al. Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity. J Am Acad Child Adolesc Psychiatry 1997;36:844-52 (Pubitemid 27250450)
21. Marcus R, Owen R, Kamen L, et al. A double-blind, randomized, placebo-controlled study of fixed-dose aripiprazole in children and adolescents with autistic disorder. J Am Acad Child Adolesc Psychiatry 2009;48:1110-19
22. Owen R, Sikich L, Marcus R, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 2009;124:1533-40
23. Aman M, Kasper W, Manos G, et al. Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder. J Child Adolesc Psychopharmacol 2010;20:415-22
24. Findling R, Marcus R, Kamen L, et al. 52-week open-label study of the safety and tolerability of aripiprazole flexibly dosed in the treatment of irritability in children and adolescents with autistic disorder. Poster presented at the 48th Annual Meeting of the American College of Neuropsychopharmacology; December 6-10, 2009; Hollywood, FL, USA
25. Robb A, Anderson C, Bellocchio E, et al. Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects. Prim Care Companion J Clin Psychiatry, in press
26. McCollough M, Owen R, Corey-Lisle P, et al. A 52-week safety and tolerability study of aripiprazole for the treatment of irritability in pediatric patients (6 - 17 years) with autistic disorder. Poster presented at the 163rd Annual Meeting of the American Psychiatric Association; May 22-26, 2010; New Orleans, LA, USA
27. Aman M, Vinks A, Remmerie B, et al. Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. Clin Ther 2007;29:1476-86 (Pubitemid 47348123)
28. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. New Engl J Med 2002;347:314-21